Long-term response to maintenance treatment with rituximab in CD20 + multiple myeloma

Leukemia and Lymphoma

Volumn 51, Issue 11, 2010, Pages 2144-2146

  Ohno, Hitoshi ^a  

^a TAKEDA GENERAL HOSPITAL   (Japan)

Author keywords

Antibody based immunotherapy; Myeloma; Prognostication

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CALCIUM; CD20 ANTIGEN; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; PROTEIN; RITUXIMAB;

AGED; ALBUMIN BLOOD LEVEL; ANEMIA; B CELL LYMPHOMA; CALCIUM BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOELECTROPHORESIS; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LEUKOCYTE COUNT; LONG TERM CARE; MAINTENANCE THERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MULTIPLE MYELOMA; REMISSION INDUCTION; TIME FACTORS;

EID: 78649313248     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.513750     Document Type: Letter

References (13)

1. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
2. Heerema-McKenney A, Waldron J, Hughes S, et al. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol 2010;133:265-270.
3. Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t (11;14) in multiple myeloma. Blood 2003;102:1070-1071.
4. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008;141:135-148.
5. Baz R, Fanning S, Kunkel L, et al. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma 2007;48:2338-2344.
6. Bergua JM, Cabrera C, Arteta EG, Prieto J. Rituximab in CD20 positive multiple myeloma. Leukemia 2008;22:1082-1083.
7. Korte W, Jost C, Cogliatti S, Hess U, Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol 1999;10:1249-1250.
8. Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2007;21:835-836.
9. Zojer N, Kirchbacher K, Vesely M, Hubl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006;47:1103-1109.
10. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
11. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
12. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336.
13. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst 2004;96:583-585.